PCA3 Test for Prostate Cancer Can Lessen the Inconveniences of PSA Screening
Based on the final recommendation made on Monday May 21, by the US Preventive Services Task Force (USPSTF) on the ineffectiveness of PSA screening, many doctors, especially members of the American Urological Association (AUA) have been against that recommendation.
While the debate on non-benefits of PSA test (as declared by the USPSTF) is still raging, DiagnoCure, a leading company in the manufacture of cancer diagnostic test is making case for its PROGENSA PCA3 test. This is a urine test that is administered to detect the PCA3 gene that is associated with prostate cancer.
The company is emphasizing the need for medical practitioners and patients to start rooting for PROGENSA PCA3 test as it provides more accurate result for early prostate cancer detection than PSA test, and can help determine if repeat biopsy is actually needed. Details on this are provided below:
DiagnoCure Inc. CA:CUR +7.14% , a Quebec life sciences company that develops and commercializes high-value cancer diagnostic tests, reported that the PROGENSA PCA3 prostate cancer diagnostic test has been featured in a number of presentations and discussions at the American Urological Association (AUA) meeting in Atlanta, GA. The value of PCA3 testing was highlighted during a debate on the new USPSFT recommendation on prostate cancer screening. PCA3 testing was the topic of 14 presentations during the meeting.
USPSTF Recommendation on Prostate Cancer Screening – Implications for PROGENSA PCA3 Test
On Monday May 21, the US Preventive Services Task Force (USPSTF) issued its final recommendation against the routine use of prostate-specific antigen (PSA)-based screening for prostate cancer. The Task Force has stated that PSA testing results in little or no reduction in prostate cancer-specific mortality and is associated with harms related to subsequent evaluation and treatments, some of which may be unnecessary. The recommendation applies to asymptomatic men in the general U.S. population, regardless of age, but does not include the use of the PSA test for surveillance after diagnosis or treatment of prostate cancer. The recommendation has been publicly criticized by the American Urological Association. The issue was debated by leading urologists during a “Town Hall” meeting at the AUA meeting earlier this week.
DiagnoCure management believes that the USPSTF recommendation may have positive implications for the use of the PROGENSA PCA3 test. The PCA3 urine test provides an opportunity to reduce the harm of PSA screening by reducing the number of unnecessary biopsies while identifying the lethal cancers. This argument in favor of PROGENSA PCA3 testing was made during a presentation at the AUA meeting by Dr. John Wei, professor at the University of Michigan.
Dr. Yves Fradet, President and Chief Medical Officer of DiagnoCure commented, “These opposing views of the USPSTF and the AUA, as well as the ongoing debate in clinical community on the most effective way to screen for prostate cancer, highlight the great need for a test like PCA3 to reduce the burden of PSA screening while maintaining the progress made in fighting this number one cancer in men.”
Clinical Data on PROGENSA PCA3
On Wednesday May 23, Dr.Wei presented results of a PROGENSA PCA3 trial conducted by the NCI Early Detection Research Network (NCI-EDRN). This was a multicenter study from 11 clinical US centers, with the objective of completing a comprehensive and independent validation of the PROGENSA PCA3 Assay for the detection of prostate cancer both in the repeat and first biopsy setting. A total of 880 eligible men were enrolled, including 305 who had a prior negative prostate biopsy. Men with a PCA3 score >60 had 80% probability of a positive biopsy while those with a PCA3 score <20 had 88% probability of having a negative biopsy. The results validated the initial hypothesis of the authors. PCA3 performance was superior to all other diagnostic tools tested in the study for the detection of any cancer and high grade cancers. The authors believe those results, which are significant improvements over classical diagnostic tools, will allow PCA3 to greatly enhance clinical decision making. Click here for the full details.
DiagnoCure is taking advantage of the raging debate started by the USPSTF to present the importance of its FDA approved screening test for prostate cancer.
With the promises of helping to reduce the burden and inconveniences of PSA test, the PCA3 could be a sound alternative or additional validated test for prostate cancer.
The American Urological Association (AUA) should take more look at this new screening procedure and compare with the actual benefits of PSA test.
This can be done even as it continues proving to the world that PSA test is still a beneficial test despite the recommendations of the US Preventive Services Task Force (USPSTF).
This HUGE 4+ Year Old Prostate Cancer Victory Authority Website:
(95% of these 1,000+ Prostate Cancer Articles on this website
are written by our Expert In -house Writers, after lots of research.
The remaining 5% are news articles and videos from relevant sources!)
- Prostate Cancer Test- Doctors Against The New Guidelines On PSA Screening
- Prostate Cancer Screening – The PSA Test and DRE Screening
- The Importance Of The PSA Test In Prostate Cancer Screening
- No Prostate Cancer PSA Screening Recommended By U.S. Health Panel – More Follow Up
- No Prostate Cancer PSA Screening Recommended By U.S. Health Panel – Follow Up – More Opposers
- Tom Perkins’ Opinion on the USPSTF Recommendations on PSA Screening
- No Prostate Cancer PSA Screening Recommended By U.S. Health Panel – Follow Up – More Condemnation From Experts – Video
- No Prostate Cancer PSA Screening Recommended By U.S. Health Panel – Follow Up – Outright Condemnation
- US Task Force Now Against Prostate Cancer PSA Test for Every Age Group
- No Prostate Cancer PSA Screening Recommended By U.S. Health Panel – Follow Up – More Speak Against It
- No Prostate Cancer PSA Screening Recommended By U.S. Health Panel – Follow – Advice Given
- Should The New Guidelines For PSA Screening Be Ignored?
- No Prostate Cancer PSA Screening Recommended By U.S. Health Panel – Follow Up – Another Urologist Opposes
- No Prostate Cancer PSA Screening Recommended By U.S. Health Panel – Follow Up – Experts Bash Panel
- No Prostate Cancer PSA Screening Recommended By U.S. Health Panel – Follow Up Oncologist Interview